Heparin-modified cationic liposome and preparation method thereof

A technology of cationic liposomes and cationic lipids, which is applied to medical preparations with non-active ingredients, medical preparations containing active ingredients, and pharmaceutical formulas, can solve problems such as limiting clinical applications and accelerating blood clearance, and achieve improved Effects of drug efficacy, safety improvement, and plasma stability improvement

Inactive Publication Date: 2017-05-31
CHINA PHARM UNIV
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, PEG-modified carriers also have many disadvantages and some problems that cannot be ignored in vivo, such as rep...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Heparin-modified cationic liposome and preparation method thereof
  • Heparin-modified cationic liposome and preparation method thereof
  • Heparin-modified cationic liposome and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] The cationic liposome of embodiment 1 heparin modification

[0029] Weigh 10 mg of egg yolk lecithin, 1 mg of cholesterol, 1 mg of dioctadecyldimethylammonium bromide, and 1 mg of curcumin in the eggplant-shaped bottle, add an appropriate amount of dichloromethane, and ultrasonically dissolve them; rotate Evaporate under reduced pressure to remove the organic solvent, and form a dry and uniform lipid film on the bottle wall; add 1 mL of distilled aqueous solution to wash the film, and hydrate at 37 ° C for 1 hour to form a liposome primary emulsion; probe ultrasonic (200W, 100 times) to obtain Blank liposomes; add 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysulfosuccinimide to enoxaparin solution at a ratio of 1: 3. Activate enoxaparin; take cationic liposome solution and an equal volume of activated enoxaparin solution (4mg / mL) and stir overnight at room temperature; remove free heparin by ultrafiltration to obtain heparin-modified cationic l...

Embodiment 2

[0034] The cationic liposome of embodiment 2 heparin modification

[0035] Weigh 15 mg of egg yolk lecithin, 2 mg of cholesterol, 1 mg of stearylamine, and 1 mg of monodemethoxycurcumin in the prescribed quantities, respectively, and place them in an eggplant-shaped bottle, add an appropriate amount of chloroform, and ultrasonically dissolve them completely; Organic solvent, form a dry and uniform lipid film on the bottle wall; add 1mL of distilled aqueous solution to wash the film, hydrate at 37°C for 1 hour to form a liposome primary emulsion, and ultrasonic probe (200W, 100 times) to obtain a blank liposome . Take the above blank liposome and add 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysulfosuccinimide to the unfractionated heparin solution at a ratio of 1: 2. Activate unfractionated heparin; take cationic liposome solution and an equal volume of activated unfractionated heparin solution (4 mg / mL) and stir overnight at room temperature; remov...

Embodiment 3

[0037] Example 3 Heparin-modified cationic liposomes

[0038]Weigh 20 mg of egg yolk lecithin, 1.5 mg of cholesterol, 1 mg of trimethylhexadecyl ammonium bromide, 1 mg of bis-demethoxycurcumin, and place them in an eggplant-shaped bottle, add an appropriate amount of methanol, and ultrasonically dissolve them completely ; Remove the organic solvent by rotary decompression evaporation, and form a dry and uniform lipid film on the bottle wall; add 1 mL of distilled aqueous solution to wash the film, and hydrate at 37 ° C for 1 hour to form a liposome primary emulsion. Probe ultrasound (200W, 100 times), To obtain blank liposomes; take the above blank liposomes and add 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride and N-hydroxyl sulfosuccinimide to dalteparin solution, the ratio is 1:4, take the cationic liposome solution and an equal volume of dalteparin sodium solution (4mg / mL) and incubate for 30min at 25°C; remove free heparin by ultrafiltration to obtain the hep...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
The average particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention relates to the field of pharmaceutical preparations, and in particular to a heparin-modified cationic liposome. The cationic liposome is characterized by consisting of 3 parts of heparin, 5-35 parts of egg yolk lecithin, 0.5-7 parts of cholesterol, 1-2 parts of a cationic material, 1 part of a medicine and 1 part of a freeze-drying protective additive. The invention also discloses a preparation method of the heparin-modified cationic liposome. The stability and safety of the heparin-modified cationic liposome provided by the invention can be obviously improved. The heparin-modified cationic liposome has functions of targeting tumor and tumor angiogenesis; and the heparin-modified cationic liposome can remarkably reduce toxic and side effects caused by chemotherapy drugs.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to a heparin-modified cationic liposome, and also discloses a preparation method of the heparin-modified cationic liposome. Background technique [0002] Cationic liposomes have the characteristics of non-immunogenicity, biodegradability, and repeatable transfection, and have been valued by relevant researchers. So far, dozens of cationic liposomes have been developed. However, studies have shown that the use of cationic liposomes alone has certain risks. After intravenous injection of cationic liposomes in experimental animals, they tend to aggregate with plasma proteins or blood cells, and attach to vascular endothelial cells through electrostatic interaction, thus causing them to be rapidly eliminated from the blood or localized in the lungs, increasing the risk of pulmonary embolism . Another toxicity of cationic liposomes is manifested as immune response. The test r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K47/69A61K47/61A61K31/12A61K9/19A61P35/00
CPCA61K9/0019A61K9/19A61K31/12A61K2300/00
Inventor 柯学李昊欢陈艺
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap